Teva Pharmaceutical Industries Limited (TEVA)
After hours:
| Previous Close | 16.80 |
| Open | 16.93 |
| Bid | 17.03 x 1400 |
| Ask | 17.16 x 3000 |
| Day's Range | 16.86 - 17.24 |
| 52 Week Range | 8.06 - 17.69 |
| Volume | |
| Avg. Volume | 9,935,083 |
| Market Cap | 19.502B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.42 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 19.71 |
Business WireTeva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
PARSIPPANY, N.J. & PARIS, July 25, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for moderate-to-severe IBD.
ZacksTEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
Business WireTeva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
TEL AVIV, Israel, July 18, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today positive topline results from its Phase 3 SPACE study evaluating the efficacy of AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years. The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. Safety data was consistent with
